Nasal Drug Delivery Market Size, Share and Industry Analysis, By Type (Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), and Nebulizers), By Application (Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and Regional Forecast, 2019-2032

The global nasal drug delivery market size stood at USD 42.39 billion in 2018 and is projected to reach USD 120.83 billion by 2032, exhibiting a CAGR of 7.9% during the forecast period. Europe dominated the global nasal drug delivery market with a share of 49.82% in 2018. The nasal drug delivery market is shaped by established local therapies and expanding interest in rapid systemic administration. Nasal sprays serve allergic rhinitis and other nasal conditions, while intranasal naloxone demonstrates the route’s value in emergency treatment. 

Commercial opportunities extend beyond established sprays. Developers are investigating nasal formulations for vaccines, peptides, and other medicines where needle-free administration or rapid absorption may offer practical advantages. A 2025 review in Nature describes renewed interest in nasal vaccines that stimulate immune responses at respiratory surfaces, while emphasizing anatomical and immunological challenges.

The nasal drug delivery market growth will depend on clinical evidence, differentiated delivery technology, manufacturing consistency, and commercial access. The strongest opportunities will pair clear therapeutic needs with reliable administration and evidence supporting claimed benefits. Forecasts should distinguish established products from investigational applications.

Nasal drug delivery has become one of the most widely researched areas over the years. Companies have developed small, portable, and user-friendly devices by adopting advanced technologies. The nasal route has been considered appropriate for delivering drugs because it provides faster onset of action for the treatment of related diseases. Recently, companies have focused on exploring new biotherapeutics to include polypeptides, peptides, and antisense DNA, which are otherwise administered via injection. These remarkable changes are likely to boost the growth of this Market.

Nasal Drug Delivery Market Key Takeaways

Market Size & Forecast

• 2018 Market Size: USD 42.39 billion
• 2032 Forecast Market Size: USD 120.83 billion
• CAGR: 7.9% during the forecast period

Market Share

• Europe dominated the global market with a 49.82% share in 2018 and is expected to retain its leading share during the forecast period.
• The dry powder inhalers (DPI) segment is projected to account for 61.1% of the market in 2025.
• The COPD application segment is expected to generate USD 35.57 billion in revenue by 2025.

Key Regional Highlights

Europe

Europe is expected to remain the leading regional market, supported by a high prevalence of COPD and asthma and strong awareness of inhaler-based therapies.

Asia Pacific

Asia Pacific is expected to see healthy growth driven by rising inhaler adoption, government awareness initiatives, and expanding biopharmaceutical investments.

China

China is projected to record strong market expansion, driven by a forecast CAGR of 10.60% during the study period.

U.S.

The market is supported by advanced respiratory disease management practices, strong healthcare infrastructure, and ongoing adoption of innovative drug delivery technologies.

Japan

The nasal drug delivery market is expected to reach USD 1.37 billion by 2025, supported by growing demand for effective respiratory treatment solutions.

Read More

Key Market Dynamics 

MARKET TRENDS

Download Free sample to learn more about this report.

Rising Adoption of Smart Inhalers Witnessed as a Significant Market Trend

For asthma and COPD patients, using an inhaler requires skill and practice to ensure device actuation. Device experts, while considering the patient's needs and demands, are trying to implement simple technologies for managing patients’ dose accuracy and easy operation. Connected or smart devices for asthma and COPD are becoming increasingly available which have proven useful in tracking and monitoring the patients' disease state. For example, in November 2019, Lupin launched a connected smart device, ADHERO, for metered-dose inhalers (MDI). Adhero, a reusable smart device with Bluetooth technology, can be attached to the top of an MDI. Smart devices using bluetooth technology detect patients’ inhaler use and remind them to take their medication. such devices thus improve adherence to asthma therapies and help keep their condition under control.  Additionally, these devices provide precise information and are easy to use.

• Europe witnessed a growth from USD 19.95 billion in 2017 to USD 21.12 Billion in 2018.

Awareness Campaigns to Boost Adoption of Inhalers for Asthma and COPD Patients

International and national government bodies are taking initiatives to conduct awareness campaigns with an aim to spread the importance and benefits of inhalers. Centers for Disease Control and Prevention (CDC) promotes awareness of asthma and its preventive measures through its initiative ‘Asthma Awareness Month’ and ‘Asthma Awareness Toolkit’. The objective of this initiative is to educate the patient population about asthma control. Companies such as Teva, Cipla and others have launched social media awareness campaigns such as ‘Inhalers are Right for Asthma,’ ‘Inhaler is a boon for Asthma’, and many more. These campaigns are encouraging patients to use more inhalers and helping them to secure their lives by taking preventive measures. This is likely to increase the demand for inhalers during the forecast period, which in turn will positively impact this Market.

The nasal drug delivery market is moving beyond conventional allergy sprays toward specialized formulations, emergency medicines, and systemic therapies. Device engineering and formulation science are increasingly developed together to improve deposition, dose consistency, and patient experience.

Intranasal emergency treatments illustrate this shift. In August 2024, the U.S. Food and Drug Administration approved Neffy, an epinephrine nasal spray for allergic reactions, introducing a needle-free alternative for eligible patients. FDA announcement. Such products highlight the commercial importance of portability, reliable administration, and rapid access.

Formulation innovation is another defining trend. Researchers are investigating dry powders, mucoadhesive excipients, and approaches that improve the stability of sensitive molecules. These technologies may support selected peptide, protein, and vaccine applications, although clinical performance remains product-specific.

Market Drivers

Increasing Prevalence of Asthma and COPD to Drive the Market

Today, millions of people are affected by pulmonary diseases, thereby increasing the overall patient population and demand for drug delivery devices. According to the World Health Organization (WHO), around 300 million people globally are suffering from asthma. The entire asthma population relies on inhalation for effective medication delivery. Industry players are continuously taking efforts to introduce patient-friendly and cost-effective devices in the market for delivering accurate results. For example, Aptar Pharma in 2018 introduced the PureHale inhaler. This inhaler is ready-to-use and portable, indicated for respiratory care. Such innovations are expected to aid in the expansion of the nasal drug delivery technology market during the forecast period.

Growing demand for convenient, non-invasive administration is supporting the nasal drug delivery market. Nasal formulations can simplify treatment for patients who struggle with swallowing tablets or require rapid intervention. Their commercial value is especially clear in allergic rhinitis and emergency medicine, where administration speed and ease of use influence treatment decisions.

Furthermore, the rise in the number of hospital admissions due to COPD is also responsible for the Nasal Drug Delivery Market growth. European countries have a significant prevalence of COPD, which is projected to increase the demand for inhalers, including DPIs and MDIs. This will further add impetus to the market during the forecast period.

Introduction of Off-patent Drugs for Respiratory Care to Consort the Supply of MDIs and DPIs

Patent expiration of branded inhaled medications and increasing pressure on the healthcare budget is leading to the development of generic inhaled medications. As the cost of treatment of asthma and COPD is reducing, it is likely to increase the awareness and adoption of DPIs and MDIs among patients. Companies are focusing on generating low-cost medications to provide cost-effective treatment. For example, in February 2019 Mylan received USFDA approval for a generic version of Advair Diskus (GlaxoSmithKline). The generic drug (Wixela Inhub) is intended to treat asthma & COPD patients and has been launched at a price lower than the brand. Moreover, growing patient awareness regarding the benefits of using DPIs and MDIs is anticipated to drive the market during the forecast period.

Established allergy treatments provide a stable demand base. Seasonal exposure, persistent symptoms, and patient preference for local therapy support continued use of nasal corticosteroids and antihistamines. Improved delivery devices and formulation design can also strengthen usability and dose consistency.

Drug developers are exploring intranasal delivery for additional therapeutic applications. Potential advantages include avoiding injections and, for selected compounds, enabling relatively rapid absorption. However, these benefits depend on the molecule, formulation, deposition, and clinical indication.

Market Restraints

Patients’ Unawareness about the Technique of Dose Administration to Hamper Market Growth

Although DPIs and MDIs have proven their efficacy in delivering accurate dose formulations, unawareness about such nasal drug delivery techniques among patient population is building failures. The most common challenge faced is the improper use of the drug delivery equipment. Lack of training and understanding among older adults is a factor responsible for unawareness. This incorrect usage and subsequent under-dosing will have inevitable effects on the patient’s health, leading to minimal adoption of the drug delivery device. This may hamper the overall market revenue during the forecast period.

Limited absorption remains a fundamental constraint on the nasal drug delivery market. The nasal cavity has a restricted dosing capacity, while mucociliary clearance removes formulations before complete absorption. These factors can reduce bioavailability and create variability between patients.

Molecule characteristics create additional barriers. Large peptides and proteins often cross nasal mucosa poorly, while enzymatic degradation can reduce drug stability. Permeation enhancers and mucoadhesive excipients may improve absorption, but their safety and tolerability require careful evaluation.

Commercial adoption also depends on affordability, clinician confidence, and patient acceptance. Developers must demonstrate meaningful advantages over oral, injectable, or inhaled alternatives. Products without clear clinical differentiation will face difficult reimbursement and market-access decisions.

Market Opportunities

The nasal drug delivery market offers opportunities where non-invasive administration addresses a clear clinical need. Emergency medicines, allergy treatments, and selected systemic therapies provide established or emerging commercial pathways. Developers will gain an advantage by demonstrating practical benefits over existing administration methods.

Emergency treatment remains a notable opportunity. Epinephrine and naloxone nasal sprays can simplify administration when patients or caregivers must act quickly. Commercial success depends on reliable dosing, clear instructions, broad availability, and appropriate clinical evidence.

Biologics represent a longer-term development opportunity. Intranasal delivery of peptides, proteins, and vaccines may reduce dependence on injections in selected applications. However, developers must overcome mucosal barriers, degradation, and limited absorption. Formulation advances will matter only when clinical studies confirm adequate exposure and therapeutic benefit.

Product lifecycle strategies offer nearer-term commercial potential. Improved spray devices, preservative systems, packaging, and patient-friendly formulations can differentiate established medicines. Generic manufacturers may also compete through dependable supply, quality, and demonstrated equivalence.

Emerging markets offer opportunities to expand access to established nasal therapies through stronger pharmacy distribution and healthcare education. Digital ordering may improve convenience where regulation permits. Across these opportunities, investment decisions should prioritize clinical differentiation, manufacturability, regulatory feasibility, and realistic reimbursement prospects.

Market Segmentation Analysis

By Type Analysis

To know how our report can help streamline your business, Speak to Analyst

Dry Powder Inhalers (DPIs) to Lead the Market

Based on type, the market is classified into dry powder inhalers (DPIs), metered dose inhalers (MDIs), and nebulizers.

Dry Powder Inhalers (DPIs)

The DPIs segment accounts for the maximum Nasal Drug Delivery Market share. Advantages of DPIs over MDIs, such as product stability, the potential to deliver low or high dose as per requirements, and low susceptibility to microorganisms, have led to the highest market value of DPIs. MDIs secure the second place in the market owing to their provision of providing metered doses to the asthmatic patients. Although MDIs are utilized by a significant amount of population, it has proved to be challenging for use by most of the patients. 

DPIs deliver medication as an inhalable powder, generally for pulmonary administration. They are not interchangeable with nasal powder devices. Nasal powders use distinct delivery designs to deposit formulations within the nasal cavity, where local absorption, mucosal contact, and clearance determine performance.

Interest in powder-based delivery reflects formulation stability, portability, and the potential to avoid some liquid-formulation limitations. However, nasal powder products require appropriate particle characteristics, reproducible metering, and device designs that support consistent deposition. Their commercial prospects depend on the molecule, intended site of action, patient technique, and evidence of clinical benefit.

Metered Dose Inhalers (MDIs)

The correct use of MDI requires multiple steps that confuse patients, making it difficult for him/her to handle the device.  This confusion makes the patient prone to multiple errors and ultimately acts as a major barrier for MDI use. Considering this, the use of DPIs is anticipated to be higher during the forecast period owing to their user-friendly approach. Nebulizers account for a comparatively smaller market share owing to their major use among hospitalized patients rather than in-home healthcare.

• By type, the dry powder inhalers (DPI) segment is expected to hold a 61.1% share in 2025.

Additionally, efforts in the introduction of effective and user-friendly DPIs in the market is forecasted to witness considerable growth during 2019-2026. For instance, in August 2019, Verona Pharma plc announced positive results from the phase 2 clinical trial for the evaluation of their dry powder inhaler indicated for COPD treatment.

MDIs typically deliver aerosolized medication to the lungs using a pressurized formulation. Conventional nasal sprays also meter a dose, but their pumps and spray geometry are designed for nasal deposition rather than pulmonary delivery. These devices therefore require separate performance assessment.

For nasal products, pump consistency, plume geometry, droplet-size distribution, actuation force, and container compatibility can affect delivered-dose performance. Device development must account for formulation viscosity and intended deposition. Manufacturers can differentiate through reliable actuation, ease of use, and validated performance across the product lifecycle.

Nebulizers

Nebulizers convert liquid medication into an aerosol for inhalation, commonly supporting respiratory treatment. They are not a standard category of nasal drug delivery devices. Their inclusion is relevant mainly where research investigates specialized aerosol delivery to the upper airway, but such systems should not be treated as equivalent to conventional intranasal products.

From a market-analysis perspective, nebulizer demand is influenced by respiratory disease management, treatment setting, device cost, and maintenance requirements. Nasal delivery assessments should keep these pulmonary applications separate unless a specific product is designed and approved for nasal administration. This distinction prevents misleading market comparisons.

By Application Analysis

Chronic Obstructive Pulmonary Disease (COPD) to Account for Maximum Share

By application, the market segments include asthma, chronic obstructive pulmonary disease (COPD), and others.

Asthma

Asthma treatment primarily relies on pulmonary inhalation devices, including pressurized metered dose inhalers, dry powder inhalers, and nebulizers. These technologies deliver medication to the lower respiratory tract and should not be grouped automatically with intranasal medicines. Nasal products may treat coexisting allergic rhinitis, which can affect patients with asthma, but they do not replace standard asthma maintenance or rescue treatment.

Chronic Obstructive Pulmonary Disease (COPD)

COPD accounts for the largest market share. According to the Centers for Disease Control and Prevention (CDC), 16 million Americans face problems breathing due to COPD every year. The rising patient population has led to the adoption of drug delivery devices, thus driving the market in terms of value. COPD patients are reliant on inhalers for medication and treatment. Asthma is anticipated to be the fastest-growing segment during the forecast period owing to increasing cases of asthma in emerging countries.

• By application, the COPD segment is projected to generate USD 35.57 billion in revenue by 2025.

Chronic obstructive pulmonary disease (COPD) is primarily treated through pulmonary drug delivery, including inhalers and nebulizers. These products target airflow limitation and other lower-respiratory symptoms. Conventional nasal delivery does not serve as a substitute for established COPD inhalation therapy.

COPD is therefore a relevant adjacent market rather than a core nasal drug delivery application. Manufacturers active in both fields may share formulation, aerosol engineering, manufacturing, or device expertise, but the intended route and clinical endpoints remain different. Revenue analysis should separate pulmonary delivery products from intranasal medicines.

By Distribution Channel Analysis

Adoption of Inhalers to Increase Significantly in Retail Pharmacies  

The nasal drug delivery technology market based on end-user industry is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. Of these, the retail and hospital pharmacies together occupy nearly half of the market share.

Retail Pharmacies

The retail pharmacies segment accounts for the leading position owing to easy availability. Due to increasing patient demand for nasal drug delivery, retail pharmacies are likely to invest in inhalers, thus increasing the market value. Retail pharmacies are important for established nasal allergy treatments, congestion relief, saline products, and certain nonprescription medicines. Their role combines product availability with pharmacist advice and consumer access.

Product selection often reflects familiarity, price, perceived effectiveness, tolerability, and convenience. Retail distribution can support repeat purchases for seasonal or recurring symptoms. Manufacturers compete through brand recognition, pharmacy relationships, product differentiation, and consistent supply.

Hospital Pharmacies

The hospital pharmacy segment accounts for the second position in this market owing to a significant rise in the number of hospital admissions for asthma and COPD patients.  Hospital pharmacies are relevant to prescription intranasal medicines, emergency treatments, and products administered within supervised care pathways. They support procurement, formulary management, medication counseling, and coordination with clinical teams.

Demand is influenced by hospital protocols, emergency preparedness, product availability, and clinical guidelines. For selected medicines, institutional adoption requires clear evidence, reliable supply, and appropriate staff training. Hospital purchasing can also depend on tender processes and budget controls.

Online Pharmacies

Online pharmacies provide ordering convenience, product comparison, and access to repeat purchases. Their relevance varies by prescription status, national regulation, delivery infrastructure, and product storage requirements.

Digital channels can help established nasal therapies reach consumers managing recurring symptoms. However, prescription verification, legitimate dispensing, product authenticity, and appropriate handling remain important safeguards. Online availability should not be confused with unrestricted access to prescription medicines.

REGIONAL ANALYSIS

To get more information on the regional analysis of this market, Download Free sample

North America Nasal Drug Delivery Market Analysis

North America benefits from established pharmaceutical manufacturing, advanced drug-device development, and broad access to prescription and nonprescription nasal therapies. The United States drives regional commercialization through regulatory pathways and emergency medicines. Demand reflects allergic rhinitis, emergency treatment, and formulation innovation. Product differentiation depends on clinical evidence, reliable devices, pharmacy access, and competitive pricing across established and emerging therapeutic applications.

United States Nasal Drug Delivery Market

The United States remains strategically important for nasal drug delivery innovation. FDA approvals of intranasal naloxone and epinephrine demonstrate the route’s role in accessible emergency treatment. Established allergy products provide recurring demand. Developers must address product-specific safety, efficacy, bioavailability, and device-performance requirements. Retail availability, clinician confidence, payer considerations, and public-health initiatives will influence commercialization and competitive positioning.

Europe Nasal Drug Delivery Market Analysis

Europe is anticipated to grow at a CAGR of 6.8% during the forecast period. The findings based on our research methodology indicate Europe to hold the largest market share during the forecast period. Europe, having the highest prevalence of COPD and asthma patients, shows signs of dominance during the forecast period. Moreover, awareness about the benefits of inhalers to treat diseases is widespread in the region. Ireland and other developing nations of Europe are witnessing a rise in asthma and COPD incidence, which is likely to boost the demand for inhalers. Acceptance of smart inhalers by the European population is likely to contribute to regional growth. 

Europe offers opportunities across established nasal allergy treatments, emergency medicines, and emerging formulations. Adoption is shaped by national healthcare systems, reimbursement arrangements, pharmaceutical regulation, and pharmacy distribution. The European Medicines Agency provides a centralized regulatory pathway for eligible medicines, while national authorities retain important responsibilities. Manufacturers must demonstrate product quality, safety, efficacy, and consistent delivery to compete across diverse healthcare markets.

Germany Nasal Drug Delivery Market

Germany’s pharmaceutical infrastructure and established healthcare system support demand for nasal medicines. Allergic rhinitis treatments, prescription therapies, and selected emergency products serve different purchasing channels. Manufacturers must meet European regulatory requirements and applicable national reimbursement or procurement conditions. Market positioning will depend on clinical differentiation, dependable supply, device usability, and pharmacy access. Formulation improvements may strengthen established products where benefits are demonstrable.

United Kingdom Nasal Drug Delivery Market

The United Kingdom provides opportunities through established pharmacy networks, prescription pathways, and demand for convenient treatments. Nasal allergy medicines support recurring use, while emergency formulations address specific clinical needs. Regulatory requirements differ from European Union arrangements following Brexit. Manufacturers must establish appropriate authorization, evidence, labeling, and distribution. Commercial performance will depend on accessibility, product reliability, clinical confidence, and effective supply management.

Asia-Pacific Nasal Drug Delivery Market Analysis

As per our market research study, Asia Pacific is expected to witness healthy growth in terms of increasing inhaler adoption. Governments in this region are keen on implementing awareness campaigns to increase the adoption of inhalers. A growing number of biopharma companies in Asia Pacific are using novel technologies to introduce DPI and MDI to the market. Also, companies are making huge investments to introduce effective and smart inhalers in the region. Rising incidences of related diseases and increasing awareness among the patient population about the advantages of inhalers is likely to contribute to the market in Asia Pacific during the forecast period.

Asia-Pacific presents diverse opportunities, ranging from established allergy therapies to emerging nasal formulations. Japan, China, India, and Australia differ in healthcare access, regulation, manufacturing capacity, and consumer purchasing behavior. Urbanization and expanding pharmaceutical capabilities support development. Affordability, local clinical evidence, distribution quality, and regulatory alignment will determine adoption. Manufacturers will need market-specific strategies rather than a single regional commercialization model.

Japan Nasal Drug Delivery Market

The nasal drug delivery market in Japan is expected to reach USD 1.37 billion by 2025. Japan offers opportunities supported by advanced pharmaceutical manufacturing, established clinical infrastructure, and demand for treatments addressing allergic rhinitis. Product development emphasizes quality, tolerability, and consistent administration. Developers must satisfy Japanese regulatory requirements and demonstrate appropriate clinical performance. Partnerships with local manufacturers and distributors can support market access. Growth prospects depend on product differentiation, reimbursement conditions, and reliable supply.

China Nasal Drug Delivery Market

China is projected to witness a strong CAGR of 10.60% during the forecast period. China combines a substantial pharmaceutical industry with expanding domestic healthcare demand. Nasal medicines address allergy symptoms and selected therapeutic needs, while novel delivery systems require product-specific clinical and regulatory evidence. Local manufacturing capabilities and distribution partnerships influence market access. Companies must navigate national approval requirements, pricing pressures, and competition from domestic suppliers. Commercial success will depend on affordability, quality, and differentiated clinical utility.

Latin America Nasal Drug Delivery Market Analysis

Latin America offers opportunities for established nasal allergy treatments and selected emergency medicines. Brazil and Mexico provide important pharmaceutical markets, although access, affordability, and distribution vary across countries. Manufacturers must navigate national registration requirements and differences in healthcare financing. Pharmacy partnerships, reliable supply, and cost-effective products will support adoption. Local regulatory expertise remains essential for sustainable regional commercialization.

Middle East & Africa Nasal Drug Delivery Market Analysis

The Middle East and Africa encompass markets with differing healthcare infrastructure, purchasing power, and pharmaceutical access. Established nasal treatments offer practical opportunities, while specialized formulations depend on regulatory readiness and affordability. Import reliance and distribution challenges can affect availability. Local partnerships, dependable supply, appropriate product registration, and pharmacy access will shape commercial performance across the region.

Nasal Drug Delivery Industry Competitive Landscape

AptarGroup, Inc. Focuses on Innovation in Drug Delivery to Strengthen its Nasal Systems Offerings

Aptar provides innovative drug delivery solutions to a wide range of consumers in pharmaceutical, healthcare, and biotechnology worldwide. The company produces six billion components and systems annually and is assessed by 1.6 million patients worldwide. According to the article published by OndrugDELIVERY in April 2018, Aptar Pharma’s regulatory team has supported 35 INDs, 31 NDAs, and 55 ANDAs in the nasal drug delivery technology itself in the last five years.

The global nasal drug delivery market features competition among pharmaceutical manufacturers, device technology providers, contract development organizations, and emerging specialty biotechnology companies. Competitive positioning depends on therapeutic differentiation, formulation performance, regulatory approvals, device reliability, manufacturing capabilities, and distribution access.

Established pharmaceutical participants include Johnson & Johnson, Pfizer, Emergent BioSolutions, and major consumer healthcare manufacturers. Johnson & Johnson competes through Spravato, an intranasal esketamine treatment, while Pfizer markets Zavzpret, a nasal migraine therapy. Emergent BioSolutions participates in emergency medicine through Narcan nasal spray. These products demonstrate how differentiated indications can create competitive opportunities beyond conventional allergy treatments.

Device specialists such as Aptar Pharma and Nemera compete through spray systems, dose consistency, usability engineering, and development support. Their technologies influence pharmaceutical partnerships because nasal delivery performance depends on the combined drug formulation and administration device. Contract manufacturers also compete by offering formulation development, filling, assembly, testing, and regulatory documentation.

ARS Pharmaceuticals entered the anaphylaxis treatment segment with Neffy, a needle free epinephrine nasal spray approved by the United States Food and Drug Administration in August 2024. Other developers are investigating intranasal peptides, vaccines, and central nervous system therapies, although clinical feasibility and commercial adoption remain uncertain.

Competitive strategies increasingly emphasize lifecycle management, product differentiation, licensing agreements, and partnerships between drug developers and device suppliers. Companies seek improved absorption, consistent dosing, convenient administration, and patient friendly packaging while maintaining acceptable manufacturing economics.

Prescription therapies, emergency medicines, over-the-counter allergy products, and device platforms operate under different purchasing models and regulatory requirements. Consequently, no single competitor dominates every nasal delivery category. Future competitive advantage will depend on clinically demonstrated benefits, scalable production, intellectual property protection, reimbursement access, and successful commercialization across selected indications and geographic markets.

LIST OF KEY COMPANIES PROFILED:

• Consort Medical plc.
• AptarGroup, Inc.
• Vectura Group plc
• 3M
• H&T Presspart Manufacturing Ltd.
• Nemera
• GOFIRE INC.
• Teva Pharmaceutical Industries Ltd.
• Others

KEY INDUSTRY DEVELOPMENTS:

• September 2025: Milestone Pharmaceuticals: CARDAMYST approval. The US FDA approved CARDAMYST (etripamil) nasal spray for adults experiencing acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT). The calcium channel blocker provides a self-administered treatment option for episodes that may otherwise require urgent medical care. The approval expanded nasal delivery into cardiovascular medicine beyond established allergy and emergency applications. 
  Milestone Pharmaceuticals, Inc.
• September 2025: Aptar Pharma and Dianosic: Intranasal scaffold partnership. The companies entered an exclusive agreement to advance a bioresorbable intranasal scaffold designed for extended local drug delivery in chronic allergic rhinitis and chronic rhinosinusitis. The partnership combines Dianosic’s scaffold technology with Aptar’s delivery expertise, with further exploration of nose-to-brain applications.
• September 2025: Corstasis Therapeutics and Aptar Pharma: Enbumyst launch milestone. Enbumyst (bumetanide nasal spray) received US FDA approval for edema associated with heart failure and certain hepatic and renal conditions in adults. Aptar’s unit-dose liquid delivery system supports administration of this intranasal diuretic, demonstrating the potential to apply nasal delivery to systemic treatment where conventional routes may present challenges.
• January 2026: Milestone Pharmaceuticals: CARDAMYST commercial availability. Milestone announced that CARDAMYST became available through US retail pharmacies, following its December 2025 approval. The company introduced a national commercialisation strategy, including a sales force and patient assistance initiatives. The launch highlights the importance of pharmacy access, reimbursement support, and patient education in converting innovative nasal medicines into commercially adopted therapies.
• March 2026: Aptar Pharma and ENA Respiratory: INNA-051 clinical development. Aptar announced that its Unidose Powder Nasal Spray System was being used in a Phase II clinical study of investigational INNA-051. The candidate is being evaluated for its potential to help protect against symptomatic viral respiratory infections. The collaboration highlights development of powder-based intranasal delivery technologies for respiratory prevention, although clinical efficacy and eventual commercialisation remain unconfirmed.

REPORT COVERAGE

The report offers qualitative and quantitative insights on nasal drug delivery and the detailed analysis of market size & growth rate for all possible segments in the market.

Along with this, the report provides an elaborative analysis of market dynamics, emerging trends, and competitive landscape. Key insights offered in the report are the technological advancements in the Nasal Drug Delivery Market, new product launches, recent industry developments such as partnerships, mergers & acquisitions, consolidated SWOT analysis of key players, business strategies of leading market players, macro and micro-economic indicators, and key industry trends.

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation